Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled “FTD, the Next Therapeutic Frontier,” which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Self-citationSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Shank3 mutant mice display autistic-like behaviours and striatal dysfunction
Peça, J., Feliciano, C., Ting, J. T., Wang, W., Wells, M. F., Venkatraman, T. N., Lascola, C. D., Fu, Z., & Feng, G. (2011) · Nature · doi:10.1038/nature09965 · Cited by 1,570
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531
Watts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M. P., & Kimonis, V. E. (2004) · Nature Genetics · doi:10.1038/ng1332 · Cited by 1,391 · cited 6×
“Of the genes that have been linked to familial forms of FTLD and ALS, MAPT, PGRN, VCP and TDP-43 all have homologs in C. elegans (only CHMP2B and FUS do not.)”
BackgroundInfluentialCan Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354
Cited by
The role of mitochondria in amyotrophic lateral sclerosis
Smith, E. F., Shaw, P. J., & De Vos, K. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2017.06.052 · Cited by 559
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Self-citationMultimodal deep learning for Alzheimer's disease dementia assessment
Qiu, S., Miller, M. I., Joshi, P. S., Lee, J. C., Xue, C., Ni, Y., Wang, Y., De Anda-Duran, I., Hwang, P. H., Cramer, J. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31037-5 · Cited by 420
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine
Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Van Deerlin, V. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 264
Self-citationBoxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228
Self-citationSchonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175
“An in vivo biomarker for tau pathology in PSP could have a transformative impact on diagnosis and drug development for this disorder.(7) Several candidate positron emission tomography (PET) radiotracers have recently been developed by screening for binding to Alzheimer disease (AD)-type tau pathology, which features a…”
Self-citationAI-based differential diagnosis of dementia etiologies on multimodal data
Xue, C., Kowshik, S. S., Lteif, D., Puducheri, S., Jasodanand, V. H., Zhou, O. T., Walia, A. S., Guney, O. B., Zhang, J. D., Poésy, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03118-z · Cited by 182
Progranulin in neurodegenerative disease
Petkau, T. L., & Leavitt, B. R. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.04.003 · Cited by 169
Self-citationFrontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
“Low serum progranulin may identify FTLD patients with a pathogenic GRN mutation resulting in progranulin haploinsufficiency (Ghidoni et al., 2008), which could be useful in monitoring potential progranulinreplacing therapies in development for FTLD (Boxer et al., 2012b).”
BackgroundBoxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citationRosen, H. J., Boeve, B. F., & Boxer, A. L. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12004 · Cited by 55
Self-citationActive lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration
Casaletto, K. B., Staffaroni, A. M., Wolf, A., Appleby, B., Brushaber, D., Coppola, G., Dickerson, B., Domoto‐Reilly, K., Elahi, F. M., Fields, J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12001 · Cited by 48
Self-citationNeuropathology of frontotemporal lobar degeneration: A review
Bahia, V. S., Takada, L. T., & Deramecourt, V. (2013) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642013dn70100004 · Cited by 48
GABAergic cortical network physiology in frontotemporal lobar degeneration
Adams, N. E., Hughes, L. E., Rouse, M. A., Phillips, H. N., Shaw, A. D., Murley, A. G., Cope, T. E., Bevan-Jones, W. R., Passamonti, L., Street, D., et al. (2021) · Brain · doi:10.1093/brain/awab097 · Cited by 47
Chu, M., Wen, L., Jiang, D., Liu, L., Nan, H., Yue, A., Wang, Y., Wang, Y., Qu, M., Wang, N., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02746-5 · Cited by 33
“The underlying mechanism of bvFTD is the accumulation and deposition of abnormal pathological proteins, especially in the frontal–temporal brain regions, including tauopathy (TAU), TAR DNAbinding protein of 43 kDa (TDP-43), and fused-in-sarcoma (FUS) [2].”
Background
Metadata
- Authors
- Boxer, A. L., Gold, M., Huey, E., Gao, F., Burton, E. A., Chow, T., Kao, A., Leavitt, B. R., Lamb, B., Grether, M., Knopman, D., Cairns, N. J., Mackenzie, I. R., Mitic, L., Roberson, E. D., Van Kammen, D., Cantillon, M., Zahs, K., Salloway, S., Morris, J., Tong, G., Feldman, H., Fillit, H., Dickinson, S., Khachaturian, Z., Sutherland, M., Farese, R., Miller, B. L., & Cummings, J.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-10-08
- Volume
- 9
- Issue
- 2
- Pages
- 176-188
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2023590402
- Cited by
- 80
- References
- 31
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.